Tech Company Financing Transactions
Artielle ImmunoTherapeutics Funding Round
Artielle ImmunoTherapeutics, based in Tigard, secured $100 thousand in funding from private investors.
Transaction Overview
Company Name
Announced On
9/9/2010
Transaction Type
Debt
Amount
$100,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7320 SW Hunziker Rd. 104
Tigard, OR 97223
USA
Tigard, OR 97223
USA
Phone
Website
Email Address
Overview
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Brock
Browse more venture capital transactions:
Prev: 9/9/2010: DataSphere venture capital transaction
Next: 9/9/2010: LiveScribe venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs